PT - JOURNAL ARTICLE AU - Kirby, James E. AU - Riedel, Stefan AU - Dutta, Sanjucta AU - Arnaout, Ramy AU - Cheng, Annie AU - Ditelberg, Sarah AU - Hamel, Donald J. AU - Chang, Charlotte A. AU - Kanki, Phyllis J. TI - SARS-CoV-2 Antigen Tests Predict Infectivity Based on Viral Culture: Comparison of Antigen, PCR Viral Load, and Viral Culture Testing on a Large Sample Cohort AID - 10.1101/2021.12.22.21268274 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.22.21268274 4099 - http://medrxiv.org/content/early/2021/12/23/2021.12.22.21268274.short 4100 - http://medrxiv.org/content/early/2021/12/23/2021.12.22.21268274.full AB - The relationship of SARS-CoV-2 antigen testing results, viral load, and viral culture detection remains to be fully defined. Presumptively, viral culture can provide a surrogate measure for infectivity of sampled individuals, and thereby inform how and where to most appropriately deploy available diagnostic testing modalities. We therefore determined the relationship of antigen testing results from three lateral flow and one microfluidics assay to viral culture performed in parallel in 181 nasopharyngeal swab samples positive for SARS-CoV-2. Sample viral loads, determined by RT-qPCR, were distributed across the range of viral load values observed in our testing population. We found that antigen tests were predictive of viral culture positivity, with the LumiraDx method showing enhanced sensitivity (90%; 95% confidence interval (95% CI) 83-94%) compared with the BD Veritor (74%, 95% CI 65-81%), CareStart (74%, 95% CI 65-81%) and Oscar Corona (74%, 95% CI 65-82%) lateral flow antigen tests. Antigen and viral culture positivity were also highly correlated with sample viral load, with areas under the receiver-operator characteristic curves (ROCs) of 0.94-0.97 and 0.92, respectively. In particular, a viral load threshold of 100,000 copies/mL was 95% sensitive (95% CI, 90-98%) and 72% specific (95% CI, 60-81%) for predicting viral culture positivity. Taken together, the detection of SARS-CoV-2 antigen identified highly infectious individuals, some of whom may harbor 10,000-fold more virus in their samples than those with any detectable infectious virus. As such, our data support use of antigen testing in defining infectivity status at the time of sampling.Competing Interest StatementWe received support from Abbott Molecular unrelated to this study under a COVID-19 Diagnostics Evaluation Agreement. One co-author, RA, was also a recipient of grant support from Abbott Molecular under a clinical study agreement. LumiraDx, Oscar Medicare Pvt. Ltd, LGC SeraCare, Abbott Molecular and Ginkgo Biosciences had no role in study design, manuscript preparation or decision to publish. All authors, no other conflicts of interest.Funding StatementThis work was supported by an Accelerating Coronavirus Testing Solutions grant from the Massachusetts Life Sciences Center. We thank LumiraDx for providing instrumentation and antigen test kits; Oscar Medicare Pvt. Ltd for providing Oscar Corona antigen test kits; and Ginkgo Biosciences (Boston, MA) for providing the CareStart antigen test kits. We thank LGC SeraCare for providing reagents used in calibrating SARS-CoV-2 viral load assays.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Committee on Clinical Investigations (CCI), the appropriately authorized Institutional Review Board (IRB) and Privacy Board appointed to review research involving human subjects at Beth Israel Deaconess Medical Center gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript